Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) observational study

被引:62
|
作者
Zettler, Marjorie E. [1 ]
Peterson, Eric D. [2 ]
McCoy, Lisa A. [2 ]
Effron, Mark B. [1 ]
Anstrom, Kevin J. [2 ]
Henry, Timothy D. [3 ]
Baker, Brian A. [4 ]
Messenger, John C. [5 ]
Cohen, David J. [6 ]
Wang, Tracy Y. [2 ]
机构
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Duke Clin Res Inst, 2400 Pratt St, Durham, NC 27705 USA
[3] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[4] Daiichi Sankyo Inc, Parsippany, NJ USA
[5] Univ Colorado, Sch Med, Aurora, CO USA
[6] St Lukes Mid Amer Heart Inst, Kansas City, MO USA
关键词
INTERVENTION INSIGHTS; CONTEMPORARY PRACTICE;
D O I
10.1016/j.ahj.2016.10.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The reasons for postdischarge adenosine diphosphate receptor inhibitor (ADPri) switching among patients with myocardial infarction (MI) are unclear. We sought to describe the incidence and patterns of postdischarge ADPri switching among patients with acute MI treated with percutaneous coronary intervention. Methods We used TRANSLATE-ACS (2010-2012) data to assess postdischarge ADPri switching among 8,672 MI patients discharged after percutaneous coronary intervention who remained on ADPri therapy 1 year post-MI. We examined patient-reported reasons for switching, GUSTO moderate or severe bleeding, major adverse cardiovascular events (MACEs), and definite stent thrombosis events around the time of the switch. Results Among patients still on ADPri therapy 1 year post-MI, 663 (7.6%) switched ADPri during that year. Switching occurred at a median of 50 days postdischarge and most frequently in patients discharged on ticagrelor (64/226; 28.3%), followed by prasugrel (383/2,489; 15.4%) and clopidogrel (216/5,957; 3.6%) (P < .001). Among patients discharged on prasugrel, 97.3% of switches were to clopidogrel and 87.5% of ticagrelor switches were to clopidogrel; both of these groups most often cited cost as a reason for switching (43.6% and 39.1%, respectively), whereas 60.7% who switched from clopidogrel cited physician decision as a reason. In the 7 days preceding the switch from clopidogrel, 40 (18.5%) had a MACE and 12 (5.6%) had a definite stent thrombosis event, whereas that from prasugrel or ticagrelor, a GUSTO moderate or severe bleeding event occurred in 1 (0.3%) and 0 patients, respectively. Conclusions Postdischarge ADPri switching occurred infrequently within the first year post-MI and uncommonly was associated with MACEs or bleeding events.
引用
收藏
页码:62 / 68
页数:7
相关论文
共 20 条
  • [1] Early Cessation of Adenosine Diphosphate Receptor Inhibitors Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention Insights From the TRANSLATE-ACS Study (Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome)
    Fosbol, Emil L.
    Ju, Christine
    Anstrom, Kevin J.
    Zettler, Marjorie E.
    Messenger, John C.
    Waksman, Ron
    Effron, Mark B.
    Baker, Brian A.
    Cohen, David J.
    Peterson, Eric D.
    Wang, Tracy Y.
    CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2016, 9 (11)
  • [2] Unplanned Inpatient and Observation Rehospitalizations After Acute Myocardial Infarction Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study
    Hess, Connie N.
    Wang, Tracy Y.
    McCoy, Lisa A.
    Messenger, John C.
    Effron, Mark B.
    Zettler, Marjorie E.
    Henry, Timothy D.
    Peterson, Eric D.
    Fonarow, Gregg C.
    CIRCULATION, 2016, 133 (05) : 493 - 501
  • [3] Treatment with Adenosine Diphosphate Receptor Inhibitors-Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study design: Expanding the paradigm of longitudinal observational research
    Chin, Chee Tang
    Wang, Tracy Y.
    Anstrom, Kevin J.
    Zhu, Baojin
    Maa, Jen-Fue
    Messenger, John C.
    Ryan, Kelley A.
    Davidson-Ray, Linda
    Zettler, Marjorie
    Effron, Mark B.
    Mark, Daniel B.
    Peterson, Eric D.
    AMERICAN HEART JOURNAL, 2011, 162 (05) : 844 - 851
  • [4] Switching of ADP Receptor Inhibitor After Hospital Discharge Among Myocardial Infarction Patients: Insights From the TRANSLATE-ACS Observational Study
    Zettler, Marjorie E.
    Peterson, Eric D.
    McCoy, Lisa A.
    Effron, Mark B.
    Anstrom, Kevin J.
    Henry, Timothy D.
    Baker, Brian A.
    Messenger, John C.
    Cohen, David J.
    Wang, Tracy Y.
    CIRCULATION, 2015, 132
  • [5] Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study
    Jackson, Larry R.
    Peterson, Eric D.
    Mccoy, Lisa A.
    Ju, Christine
    Zettler, Marjorie
    Baker, Brian A.
    Messenger, John C.
    Faries, Douglas E.
    Effron, Mark B.
    Cohen, David J.
    Wang, Tracy Y.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2016, 5 (10):
  • [6] Association of Discharge Aspirin Dose With Outcomes After Acute Myocardial Infarction Insights From the Treatment with ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) Study
    Xian, Ying
    Wang, Tracy Y.
    McCoy, Lisa A.
    Effron, Mark B.
    Henry, Timothy D.
    Bach, Richard G.
    Zettler, Marjorie E.
    Baker, Brian A.
    Fonarow, Gregg C.
    Peterson, Eric D.
    CIRCULATION, 2015, 132 (03) : 174 - 181
  • [7] In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study
    Bagai, Akshay
    Peterson, Eric D.
    Honeycutt, Emily
    Effron, Mark B.
    Cohen, David J.
    Goodman, Shaun G.
    Anstrom, Kevin J.
    Gupta, Anjan
    Messenger, John C.
    Wang, Tracy Y.
    EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE, 2015, 4 (06) : 499 - 508
  • [8] Early Medication Nonadherence After Acute Myocardial Infarction Insights into Actionable Opportunities From the TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) Study
    Mathews, Robin
    Peterson, Eric D.
    Honeycutt, Emily
    Chin, Chee Tang
    Effron, Mark B.
    Zettler, Marjorie
    Fonarow, Gregg C.
    Henry, Timothy D.
    Wang, Tracy Y.
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2015, 8 (04): : 347 - 356
  • [9] The safety and effectiveness of adenosine diphosphate receptor inhibitor pretreatment among acute myocardial infarction patients treated with percutaneous coronary intervention in community practice: Insights from the TRANSLATE-ACS study
    Effron, Mark B.
    Wang, Tracy Y.
    Fonarow, Gregg C.
    Henry, Timothy D.
    Zettler, Marjorie E.
    Baker, Brian A.
    McCoy, Lisa A.
    Peterson, Eric D.
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2018, 91 (02) : 242 - 250
  • [10] Antiplatelet Therapy Changes for Patients With Myocardial Infarction With Recurrent Ischemic Events: Insights Into Contemporary Practice From the TRANSLATE-ACS (Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome) Study
    Fanaroff, Alexander C.
    Kaltenbach, Lisa A.
    Peterson, Eric D.
    Akhter, Mohammed W.
    Effron, Mark B.
    Henry, Timothy D.
    Wang, Tracy Y.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2018, 7 (04):